Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Johnson & Johnson (NY:JNJ)

151.33 +1.72 (+1.15%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails
From Nachawati Law Group
Via Business Wire
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson expands efforts to champion the nursing workforce globally
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Reports Q1 2025 Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition
From Johnson & Johnson
Via Business Wire
Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts
From Beasley Allen Law Firm
Via Business Wire
Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations
From Johnson & Johnson
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
From Johnson & Johnson
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
Johnson & Johnson Reports Q4 and Full-Year 2024 Results
From Johnson & Johnson
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)
From Brodsky & Smith LLC
Via GlobeNewswire
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
From Johnson & Johnson
Via Business Wire
Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
Inovalon Unveils New Research, Products, and Solutions to Tackle Healthcare’s Most Complex Challenges 
From Inovalon Holdings, Inc.
Via GlobeNewswire
Johnson & Johnson Stock: Setting the Stage for 2025 Highs
Healthcare giant and Dividend Aristocrat Johnson & Johnson is on track to hit new highs in 2025 and may sustain its rally well into 2026. 
Via MarketBeat
Exposures COVID-19
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Reports Q3 2024 Results
From Johnson & Johnson
Via Business Wire
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.